Results 141 to 150 of about 97,696 (193)
2.2Å ブンカイノウ デノ ヒト ユライ モノアミン サンカ コウソA ノ ケッショウ コウゾウ ト ソノ マクカンツウ ヘリックス ノ キノウテキ ヤクワリ [PDF]
Son, Seyoung +2 more
core
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Topics in Medicinal Chemistry, 2019
The development of xanthine oxidase and monoamine oxidase inhibitors led to important breakthroughs in the therapy of oxidative damage, hyperuricemia, gout, neurological, neuropsychiatric disorders and management of reperfusion injury.
Neelam Malik +3 more
semanticscholar +1 more source
The development of xanthine oxidase and monoamine oxidase inhibitors led to important breakthroughs in the therapy of oxidative damage, hyperuricemia, gout, neurological, neuropsychiatric disorders and management of reperfusion injury.
Neelam Malik +3 more
semanticscholar +1 more source
Monoamine oxidase‐B inhibitors as potential neurotherapeutic agents: An overview and update
Medicinal research reviews (Print), 2019Monoamine oxidase (MAO) inhibitors have made significant contributions and remain an indispensable approach of molecular and mechanistic diversity for the discovery of antineurodegenerative drugs.
R. Tripathi, S. R. Ayyannan
semanticscholar +1 more source
Expert Opinion on Therapeutic Patents, 2002
Forty-nine monoamine oxidase inhibitor (MAOI)-related patents published between January 1998 and July 2002 are included in this review. They are classified and reviewed under three categories: (i) novel chemical entities, (ii) novel formulations, delivery systems and processing methods of known MAOIs and (iii) novel utilities and/or pharmaceutical ...
openaire +4 more sources
Forty-nine monoamine oxidase inhibitor (MAOI)-related patents published between January 1998 and July 2002 are included in this review. They are classified and reviewed under three categories: (i) novel chemical entities, (ii) novel formulations, delivery systems and processing methods of known MAOIs and (iii) novel utilities and/or pharmaceutical ...
openaire +4 more sources
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status
Expert Opinion on Drug Metabolism & Toxicology, 2019Introduction: Brain function depends considerably on the neurotransmission of biogenic monoamines. Their metabolism employs monoamine oxidase-B in neuronal and glial cells. Inhibition of monoamine oxidase-B elevates biogenic amine levels.
T. Müller, Jan-Dominique Möhr
semanticscholar +1 more source
Pyrogens and Monoamine Oxidase Inhibitors [PDF]
Nature, 1966 MANY nerve terminals within the hypothalamus contain either noradrenaline or 5-hydroxytryptamine (5-HT) (ref. 1). It has been suggested that these amines may play a part in the thermo-regulatory pathways2–4.
W. I. Cranston, K. E. Cooper
openaire +2 more sources
Monoamine Oxidase B Inhibitors in Parkinson's Disease.
CNS and Neurological Disorders - Drug Targets, 2017BACKGROUND Parkinson's disease (PD) is a neurodegenerative disorder with a prevalence increasing with age. Oxidative stress and glutamate toxicity are involved in its pathomechanism.
L. Dézsi, L. Vécsei
semanticscholar +1 more source
Targeting monoamine oxidase A for T cell–based cancer immunotherapy
Science immunology, 2021Monoamine oxidase A (MAO-A) restrains antitumor T cell immunity, suggesting potential use of MAO-A inhibitors in cancer immunotherapy. Repurposing antidepressants for cancer immunotherapy Antibodies targeting immune checkpoints that restrain the ...
Xi Wang +21 more
semanticscholar +1 more source
Monoamine Oxidase Inhibitors [PDF]
, 2004 The monoamine oxidase inhibitors (MAOIs) have been in clinical use for five decades. The coincidental discovery that inhibiting brain monoamine oxidase resulted in antidepressant benefits indirectly led to the norepinephrine (NE) and serotonin hypotheses for depression.
Glen B. Baker, S. H. Kennedy, A. Holt
openaire +1 more source